Rocakinogene Sifuplasmid

also known as INO9012 · MEDI0457 · IL-12 DNA adjuvant · INO-3112 · Rocakinogen sifuplasmida · Rocakinogene sifuplasmide

Developed for: hepatocellular carcinoma · cervical cancer · glioblastoma · head and neck cancer · anal canal carcinoma · breast cancer · cervical carcinoma · colorectal cancer
+20 more
· esophageal cancer · gastric cancer · head and neck squamous cell carcinoma · hepatitis C virus infection · hereditary neoplastic syndrome · HIV infectious disease · human papilloma virus infection · human papillomavirus-related squamous cell carcinoma · lung cancer · malignant pancreatic neoplasm · metastatic malignant neoplasm · oropharynx squamous cell carcinoma · ovarian cancer · penile carcinoma · preneoplastic lesion · prostate cancer · urothelial carcinoma · vaginal carcinoma · virus associated tumor · vulvar carcinoma
Investigated by: Inovio Pharmaceuticals · University of Pennsylvania · Geneos Therapeutics · National Cancer Institute (NCI) · Abramson Cancer Center at Penn Medicine · AstraZeneca
+16 more
· Barbara Ann Karmanos Cancer Institute · Centre Hospitalier Universitaire Vaudois · Defense Advanced Research Projects Agency · European Organisation for Research and Treatment of Cancer - EORTC · GeneOne Life Science, Inc. · M.D. Anderson Cancer Center · Mayo Clinic · MedImmune LLC · National Institute of Allergy and Infectious Diseases (NIAID) · National Institute of Neurological Disorders and Stroke (NINDS) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · The Foundation for Barnes-Jewish Hospital · Thomas Jefferson University · University of North Carolina · University of Pittsburgh · Washington University School of Medicine

Trials 17 · a red edge is where a trial was stopped

today NCT04367675 · Ph 1 NCT04015700 · Ph 1 NCT04251117 · Ph 1/2 NCT04001413 · Ph 2 NCT03439085 · Ph 2 NCT03491683 · Ph 1/2 NCT03502785 · Ph 1/2 NCT03162224 · Ph 1/2 NCT02772003 · Ph 1 NCT02501278 · Ph 2 NCT02514213 · Ph 1 NCT02464670 · Ph 1 NCT02960594 · Ph 1 NCT02163057 · Ph 1/2 NCT02172911 · Ph 1/2 NCT02241369 · Ph 1 NCT00115960 · Ph 1

20082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 18 trials
Phase 1	NCT04367675	Apr 2021 → Dec 2026 expected	hereditary neoplastic syndrome	Abramson Cancer Center at Penn Medicine	Active not recruiting	No outcome recorded
Phase 1	NCT04015700	Jul 2020 → May 2022 overdue	glioblastoma	Washington University School of Medicine	Active not recruiting	No outcome recorded
Phase 1	NCT02772003	Jun 2016 → Mar 2020 overdue	hepatitis C virus infection, hepatocellular carcinoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1	NCT02514213	Jul 2015 → Dec 2017	prostate cancer	Inovio Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT02464670	May 2015 → May 2018	Ebola hemorrhagic fever	Inovio Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT02960594	Dec 2014 → Nov 2018	breast cancer, colorectal cancer, esophageal cancer, gastric cancer +5	Inovio Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT02241369	May 2014 → Sep 2018	preneoplastic lesion	Inovio Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT00115960	? → Jul 2008	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/26 trials
Phase 1/2	NCT04251117	Mar 2020 → Nov 2024 overdue	hepatocellular carcinoma	Geneos Therapeutics	Active not recruiting	No outcome recorded
Phase 1/2	NCT03491683	May 2018 → Dec 2026 expected	glioblastoma	Inovio Pharmaceuticals	Active not recruiting	No outcome recorded
Phase 1/2	NCT03502785	May 2018 → May 2025	urothelial carcinoma	Inovio Pharmaceuticals	Completed	No outcome recorded
Phase 1/2	NCT03162224	Jun 2017 → Mar 2021	head and neck cancer, human papilloma virus infection	MedImmune LLC	Completed	No outcome recorded
Phase 1/2	NCT02163057	Aug 2014 → Jan 2017	head and neck squamous cell carcinoma	Inovio Pharmaceuticals	Completed	No outcome recorded
Phase 1/2	NCT02172911	Jun 2014 → Sep 2017	cervical cancer	Inovio Pharmaceuticals	Completed	No outcome recorded
Phase 23 trials
Phase 2	NCT04001413	Sep 2019 → Mar 2021	human papillomavirus-related squamous cell carcinoma, oropharynx squamous cell carcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Withdrawn	No outcome recorded
Phase 2	NCT03439085	Nov 2018 → Sep 2022	anal canal carcinoma, cervical carcinoma, metastatic malignant neoplasm, penile carcinoma +3	M.D. Anderson Cancer Center	Terminated	No outcome recorded
Phase 2	NCT02501278	May 2016 → May 2019	cervical cancer	European Organisation for Research and Treatment of Cancer - EORTC	Withdrawn	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT03606213 Comparator	Aug 2018 → May 2021	HIV infectious disease	Steven Deeks	Completed	No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 19 sources stand behind the page.

Field	Value	Cited text
Known as	Rocakinogene Sifuplasmid	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02772003 ↗
Known as	IL-12 DNA adjuvant	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00115960 ↗
Known as	INO-3112	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02172911 ↗
Known as	INO9012	“2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P” NCT02514213 ↗ 12 “INO-9012 (1 mg dose IM): A synthetic plasmid that expresses human interleukin-12 (IL-12).” NCT03502785 ↗ “INO-3112 i.e. the combination of VGX-3100 and INO-9012, specifically:” NCT02501278 ↗ “1 mg of INO-9012 (DNA plasmid encoding human interleukin 12)” NCT02163057 ↗ “The INO-9012 vials will be supplied by Geneos Therapeutics” NCT04015700 ↗ NCT02464670 ↗ NCT02241369 ↗ NCT02960594 ↗ NCT03606213 ↗ NCT02514213 ↗ NCT04367675 ↗ NCT04251117 ↗ NCT03491683 ↗
Known as	MEDI0457	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03162224 ↗ 2 NCT03439085 ↗ NCT04001413 ↗
Known as	Rocakinogen sifuplasmida	ChEMBL registry synonym — accepted as the source's own label CHEMBL4594560 ↗
Known as	Rocakinogene sifuplasmide	ChEMBL registry synonym — accepted as the source's own label CHEMBL4594560 ↗
Modality	Vaccine	“INO-3112 DNA vaccines” NCT02172911 ↗
Route	Intramuscular	“1.1 mL intramuscular (IM) injection of INO-3112 (VGX-3100 + INO-9012) was administered” NCT02172911 ↗